Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed / refractory multiple myeloma

Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed / refractory multiple myeloma

Multiple myeloma (MM) patients are often refractory to targeted therapies including proteasome inhibitors (PIs). Here, analysis of RNA sequencing data derived from 672 patients with newly diagnosed or relapsed/refractory disease identified the acid ceramidase, ASAH1, as a key regulator of PI resist...

Full description

Bibliographic Details
Main Authors: Ryan T. Bishop, Tao Li, Praneeth Sudalagunta, Mostafa Nasr, Karl J. Nyman, Raghunandan R. Alugubelli, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Bin Fang, Steven Grant, John Koomen, Ariosto S. Silva, Kenneth H. Shain, Conor C. Lynch
Format: Article
Language:English
Published: Ferrata Storti Foundation 2024-12-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11859

Internet

https://haematologica.org/article/view/11859

Similar Items